Global Information
회사소개 | 문의 | 비교리스트

리바록사반(Rivaroxaban) 시장 : 규모, 점유율, 동향, 예측(-2026년)

Rivaroxaban Market - Size, Share, Trends, and Forecast to 2026

리서치사 Coherent Market Insights
발행일 2018년 07월 상품 코드 785774
페이지 정보 영문
가격
US $ 4,500 ₩ 5,391,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,387,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 11,982,000 PPT Turned PDF (Enterprise User License)


리바록사반(Rivaroxaban) 시장 : 규모, 점유율, 동향, 예측(-2026년) Rivaroxaban Market - Size, Share, Trends, and Forecast to 2026
발행일 : 2018년 07월 페이지 정보 : 영문

리바록사반(Rivaroxaban)은 Johnson&Johnson의 자회사인 Janssen Pharmaceuticals Inc.가 자렐토(Xarelto)라는 브랜드명으로 판매하고 있는 항응고제입니다. 적응증을 늘리기 위한 임상시험 증가가 리바록사반 시장 성장 주요인이 될 것으로 예측됩니다.

세계의 리바록사반(Rivaroxaban) 시장을 조사했으며, 시장 개요, 용량·용도·유통채널·시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 개요

  • 보고서 설명
  • 시장 정의와 범위
  • 주요 요약
    • 시장 개요 : 용량별
    • 시장 개요 : 용도별
    • 시장 개요 : 유통채널별
    • 시장 개요 : 지역별
  • Coherent Opportunity Map(COM)

제3장 시장 역학, 규제, 동향 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • 업계 동향
  • 규제 시나리오
  • 역학

제4장 세계의 리바록사반 시장 : 용량별

  • 서론
  • 10mg
  • 15mg
  • 20mg

제5장 세계의 리바록사반 시장 : 용도별

  • 서론
  • 심부정맥 혈전증 예방
  • 폐색전증

제6장 세계의 리바록사반 시장 : 유통채널별

  • 서론
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 세계의 리바록사반 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 프랑스
    • 스페인
    • 러시아
    • 기타
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • ASEAN 국가
    • 호주
    • 한국
    • 기타
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 아르헨티나
    • 기타
  • 중동
    • 걸프협력회의(GCC)
    • 이스라엘
    • 기타
  • 아프리카
    • 북아프리카
    • 중앙아프리카
    • 남부아프리카

제8장 경쟁 환경

  • 히트 맵 해석
  • 기업 개요
    • Janssen Pharmaceuticals Inc.
    • Bayer AG
  • 애널리스트의 견해

제9장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights에 대해
LSH 19.03.04

Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.

Market Dynamics

Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.

Key features of the study:

This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics

The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts

Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Rivaroxaban Market, By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • Global Rivaroxaban Market, By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • Global Rivaroxaban Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Rivaroxaban Market, By Region:
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By country:
  • Germany
  • U.K.
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Strength:
  • 10 mg
  • 15 mg
  • 20 mg
  • By Application:
  • Deep Vein Thrombosis Prophylaxis
  • Pulmonary Embolism
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By country:
  • North Africa
  • Central Africa
  • South Africa
  • Company Profiles
  • Janssen Pharmaceuticals Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
  • Bayer AG
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
  • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Strength
    • Market Snippet, By Application
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Industry Trends
  • Regulatory Scenario
  • Epidemiology

4. Global Rivaroxaban Market, By Product Type, 2016 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • 15 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • 20 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

5. Global Rivaroxaban Market, By Application, 2016-2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Deep Vein Thrombosis Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Pulmonary Embolism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

6. Global Rivaroxaban Market, By Distribution Channel, 2016-2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Million)

7. Global Rivaroxaban Market, By Regions, 2016-2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • U.S.
  • Canada
  • Europe
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Strength, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Application, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
  • Northern Africa
  • Central Africa
  • South Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Janssen Pharmaceuticals Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
    • Bayer AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top
전화 문의
F A Q